WuXi Biologics Recognized as Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics for Fifth Consecutive Year
Ranked among the top 1% of companies assessed in the pharmaceutical industry Recognized as a leader in Green CRDMO, driving innovation for a healthier future Committed to creating long-term value for all stakeholders SHANGHAI, Feb. 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it...
BioRay’s ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA
SHANGHAI, Feb. 10, 2025 /PRNewswire/ -- On December 19, 2024, BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application for its self-developed Class 1 innovative therapeutic biological product, BR111 for injection. BR111 is an antibody-drug conjugate (ADC) targeting dual epitopes of ROR1, intended for the treatment of ROR1-positive hematological...
Caliway Announces CBL-514 Second Phase 2b Study Results (CBL-0205) Met Endpoints
CBL-514, the world's first investigational drug for large-area localized fat reduction, has demonstrated significant efficacy in its second and the last Phase 2b study (CBL-0205) before Phase 3. 54.2% of participants in the CBL-514 group achieved at least 20% fat volume reduction four weeks after treatment. Nearly 80% of the CBL-514...
NUS scientists develop realistic ‘micro-gut’ model to study the relationship between gut microbes and human diseases
The 3D scalable 'gut-on-a-chip' model enables real-time visualisation of the interactions of gut microbes and the human intestine SINGAPORE, Feb. 10, 2025 /PRNewswire/ -- In a breakthrough for the advanced study of gut health, scientists from the National University of Singapore (NUS) have developed a 3D microscopic version of the human intestines...
CStone Announces Inclusion of Cejemly® (sugemalimab) as a First-Line Combination Therapy for NSCLC in ESMO Guideline
SUZHOU, China, Feb. 10, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that its key product, Cejemly® (sugemalimab), has been included in the European Society for Medical Oncology (ESMO) Non-Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer (NSCLC) Living Guideline. Sugemalimab is recommended as a first-line combination therapy for both...
2025 Singclean Global Aesthetic Master Symposium Debuted in France
PARIS, Feb. 10, 2025 /PRNewswire/ -- 2025 IMCAS World Congress, the world's largest scientific aesthetics congress, was grandly held in Paris from January 30 to February 1, celebrating its 26th anniversary. SINGCLEAN highlight video in IMCAS 2025 Singclean Medical showcased its flagship HA fillers, Singfiller and Singderm, along with...
CARsgen’s First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T Trial Achieves sCR at Week 4
SHANGHAI, Feb. 10, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the first subject treated with an allogeneic BCMA CAR-T therapy developed on the THANK-u Plus™ platform, has achieved stringent complete...
HICC Pet® Launches Pet Care Academy of Magic at Pet Show Hong Kong 2025
Transforming Pet Care into a Magical Adventure: HICC Pet® offers spa-like grooming and healthcare while educating pet owners on maintaining their pets' wellness. HONG KONG, Feb. 7, 2025 /PRNewswire/ -- From February 6 to 9, 2025, the HICC Pet brand is showcasing its groundbreaking grooming and healthcare products at the Hong Kong Convention and Exhibition Centre during the Pet Show Hong Kong...
Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
CHENGDU, China, Feb. 8, 2025 /PRNewswire/ -- KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of Stapokibart (anti-IL-4Rα monoclonal antibody, trade name: Kangyueda (康悦达), for the treatment of seasonal allergic rhinitis. The approval is based on a multi-center, randomized, double-blind, placebo-controlled...
‘The convergence between of AI and the Biology’ LG Creates “Next-Generation Protein Structure Prediction AI” for Drug Discovery
SEOUL, South Korea, Feb. 7, 2025 /PRNewswire/ -- On the 5th, LG AI Research signed a joint research agreement at the Global Lounge of LG Science Park in Magok, Gangseo-gu, Seoul, with Prof. Min-Kyung Baek from the school of Biological Sciences at Seoul National University to develop a "next-generation protein structure prediction AI." LG...
